Invasive Oral Procedures and Events in Postmenopausal Women With Osteoporosis Treated With Denosumab for Up to 10 Years
- 13 February 2019
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 104 (6), 2443-2452
- https://doi.org/10.1210/jc.2018-01965
Abstract
Context Antiresorptive therapy has been associated with osteonecrosis of the jaw (ONJ), an infrequent but potentially serious adverse event. Objective To assess information on invasive oral procedures and events (OPEs) – dental implants, tooth extraction, natural tooth loss, scaling/root planing, jaw surgery – during the 7-year FREEDOM Extension and to present details of positively adjudicated ONJ cases. Design Randomized, double-blind, placebo-controlled 3-year trial (FREEDOM) followed by 7 years of open-label denosumab (FREEDOM Extension). At Extension Year 3, women were asked to record their history of invasive OPEs since the start of the Extension to Year 2.5 and oral events in the prior 6 months. The questionnaire was then administered every 6 months (Q6M) until the end of the Extension. Setting Multicenter, multinational clinical trial. Patients Women with postmenopausal osteoporosis. Interventions Subcutaneous denosumab 60mg or placebo Q6M for 3-years, then 7 years of open-label denosumab. Main Outcome Measures Self-reports of OPEs and adjudicated cases of ONJ. Results 45.1% of respondents reported at least one invasive OPE. The exposure-adjusted ONJ rate in FREEDOM Extension was 5.2 per 10,000 subject-years. ONJ incidence was higher in those reporting an OPE (0.68%) than not (0.05%). Conclusions While invasive OPEs were common in these denosumab-treated women and were associated with an increased ONJ incidence, the overall rate of ONJ was low, and all cases with complete follow-up resolved with treatment.Keywords
Funding Information
- Amgen
This publication has 27 references indexed in Scilit:
- Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extensionJournal of Bone and Mineral Research, 2011
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyThe Lancet, 2011
- American Association of Oral and Maxillofacial Surgeons Position Paper: Bisphosphonate-Related Osteonecrosis of the Jaws—2009 Update: The Need to Refine the BRONJ DefinitionJournal of Oral and Maxillofacial Surgery, 2009
- Longitudinal Cohort Study of Risk Factors in Cancer Patients of Bisphosphonate-Related Osteonecrosis of the JawJournal of Clinical Oncology, 2009
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisThe New England Journal of Medicine, 2009
- Clinical Investigation of C-Terminal Cross-Linking Telopeptide Test in Prevention and Management of Bisphosphonate-Associated Osteonecrosis of the JawsJournal of Oral and Maxillofacial Surgery, 2009
- American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws—2009 UpdateJournal of Oral and Maxillofacial Surgery, 2009
- Bisphosphonate-Related Osteonecrosis of the Jaws: A Case-Control Study of Risk Factors in Breast Cancer PatientsJournal of Clinical Oncology, 2008
- Factors Associated with Osteonecrosis of the Jaw among Bisphosphonate UsersThe American Journal of Medicine, 2008
- Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral ResearchJournal of Bone and Mineral Research, 2007